PD-1 versus Car-T: stop making sense
T-cell exhaustion, a frequently cited reason for Car-T relapse, might be reversed by PD-(L)1 blockade; but is exhaustion really the problem?
T-cell receptor behemoths consolidate? Not quite
Adaptimmune merges with TCR2, but the move is effectively an equity raise with benefits.
Novo sows the seeds for a new heart failure approach
The company reckons it can succeed where other cell therapies have failed, but proof is a long way off.
Fate runs out of excuses
The plug is pulled on a deal with J&J, and Fate swings the axe over its staff and NK cell pipeline.
Remarkably, interest in BCMA continues
But, as Celyad bows out, how do you compete in a field as crowded as this?